Compare · DFTX vs SNDL
DFTX vs SNDL
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and SNDL Inc. (SNDL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and SNDL operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.53B, about 6.7x SNDL ($377.4M).
- Over the past year, DFTX is up 214.5% and SNDL is up 8.7% - DFTX leads by 205.8 points.
- DFTX has been more active in the news (3 items in the past 4 weeks vs 1 for SNDL).
- Both have 4 recent analyst ratings on file.
PerformanceDFTX+214.48%SNDL+8.68%
2025-06-11+0.00%2026-06-10
- Company
- Definium Therapeutics Inc.
- SNDL Inc.
- Price
- $23.24+1.31%
- $1.44-1.37%
- Market cap
- $2.53B
- $377.4M
- 1M return
- +8.55%
- +1.05%
- 1Y return
- +214.48%
- +8.68%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 3
- 1
- Recent ratings
- 4
- 4
SNDL
SNDL Inc.
Sundial Growers Inc. engages in production and marketing of cannabis products for the adult-use market in Canada. It produces and distributes inhalable products, such as flower, pre-rolls, and vapes. The company offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. Sundial Growers Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Latest SNDL
- SNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis Stores
- SEC Form 6-K filed by SNDL Inc.
- SNDL Reports First Quarter 2026 Financial and Operational Results
- SEC Form 6-K filed by SNDL Inc.
- SEC Form 6-K filed by SNDL Inc.
- SNDL to Report First Quarter 2026 Financial Results on April 29, 2026
- SEC Form 6-K filed by SNDL Inc.
- SNDL Announces Leadership Transition for Cannabis Segment
- SEC Form 6-K filed by SNDL Inc.
- SNDL Reports Fourth Quarter and Full Year 2025 Financial and Operational Results